refusing hormone therapy for breast cancer postmenopausal

Release time ：Dec-25,2024

Declining hormone therapy in postmenopausal breast cancer patients could result in faster tumor growth and reduced survival rates. Hormone therapy is a crucial component of breast cancer treatment, particularly for those with hormone receptor-positive tumors.

Hormone therapy works by either blocking the effects of estrogen or by lowering the body's estrogen levels to suppress tumor growth. Patients who refuse this treatment may see their tumors continue to grow unchecked. Moreover, clinical research has demonstrated that patients who undergo hormone therapy have higher survival rates and a lower risk of recurrence compared to those who decline it. Additionally, with advancements in medical technology, the side effects of hormone therapy have been effectively managed and controlled, diminishing the justification for patients to refuse treatment due to side effect concerns.

Ultimately, for postmenopausal breast cancer patients, we strongly advocate for receiving standardized hormone therapy under the supervision of a qualified physician. Patients should also vigilantly monitor their health, engage in regular check-ups, and adhere to the treatment adjustments recommended by their doctors. Remember, the use of any medication should always be under the guidance of a healthcare professional, and self-determination regarding medication use is not advisable.